676 related articles for article (PubMed ID: 29438562)
21. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
Frampton JE; Keam SJ
Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age.
Marshall GS; Pool V; Greenberg DP; Johnson DR; Sheng X; Decker MD
Clin Vaccine Immunol; 2014 Nov; 21(11):1560-4. PubMed ID: 25230939
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response.
Halperin SA; Langley JM; Ye L; MacKinnon-Cameron D; Elsherif M; Allen VM; Smith B; Halperin BA; McNeil SA; Vanderkooi OG; Dwinnell S; Wilson RD; Tapiero B; Boucher M; Le Saux N; Gruslin A; Vaudry W; Chandra S; Dobson S; Money D
Clin Infect Dis; 2018 Sep; 67(7):1063-1071. PubMed ID: 30010773
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.
Scott LJ
Paediatr Drugs; 2011 Apr; 13(2):133-5. PubMed ID: 21351814
[TBL] [Abstract][Full Text] [Related]
26. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
27. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
[TBL] [Abstract][Full Text] [Related]
28. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
[TBL] [Abstract][Full Text] [Related]
29. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
30. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
31. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
32. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
33. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults.
Weston WM; Chandrashekar V; Friedland LR; Howe B
Hum Vaccin; 2009 Dec; 5(12):858-66. PubMed ID: 19838080
[TBL] [Abstract][Full Text] [Related]
36. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
37. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
38. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
[TBL] [Abstract][Full Text] [Related]
39. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
Scott LJ
BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults.
Turnbull FM; Heath TC; Jalaludin BB; Burgess MA; Ramalho AC
Vaccine; 2000 Nov; 19(6):628-36. PubMed ID: 11090714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
